Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04323189

Effects of Sitagliptin in Individuals With Genetically Decreased DPP4

This is a pilot clinical trial to test the hypothesis that during sitagliptin (DPP4 inhibitor), individuals heterozygous for DPP4 loss of function variants will have a reduction in DPP4 activity and antigen, lower glucose after a mixed meal, and higher levels of intact DPP4 substrates compared to during placebo and compared to matched controls.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Age range

18 year–80 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 4

Primary location

University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States

About this study

Participants of this pilot clinical trial will be randomized in a blinded 2:2 crossover manner to receive placebo and sitagliptin 100 mg/d (DPP4 inhibitor), in random order. Subjects will receive each intervention for seven days, with a study day on day 7. Each intervention will be separated by a 4-week washout period. Each subject will have up to four separate visits: 1) DXA, echocardiogram, 2) cardiac MRI, 3) mixed meal during placebo, 4) mixed meal during sitagliptin.

The study will include 10 cases (heterozygous for DPP4 loss of function variant) and 10 controls.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Participant of the Penn Medicine Biobank who is willing to be recontacted to participate in future research.
  • Cases are defined as adults 18-70 years with likely decreased DPP4.
  • Controls are defined as adults who are matched to cases by: age, gender, race, BMI, hypertension status, diabetes status, renal function, and medication use that may affect outcomes of interest.

Exclusion criteria

  • The study will exclude volunteers with any significant medical conditions that may interfere with study participation, data interpretation, or pose safety risk(s) to the subject.
  • Recent hospitalization or acute illness such as infection within the past two weeks
  • Pregnancy
  • Use of insulin
  • Use of a GLP-1 agonist or DPP4 inhibitor medication
  • Use of oral diabetes agents other than metformin unless matched with controls
  • Type 1 diabetes
  • Chronic steroid use or use within the last 30 days
  • Significant liver disease including liver enzymes >3 x upper limit of normal range
  • Renal dysfunction defined as eGFR< 50mL/min/1.73m2
  • Significant cardiac disease such as heart transplantation
  • Significant gastrointestinal conditions that may interfere with drug absorption or GLP-1 release including bariatric surgery
  • Significant hematologic disease such as hematocrit <35%
  • Use of chronic anticoagulation
  • Severe pulmonary disease
  • Severe neurologic or psychiatric disease
  • Inability to comprehend study procedures

Treatment and study plan

Sitagliptin 100mg

Drug

Sitagliptin will be administered daily for 7 days, with a study day on day 7.

Other names: Januvia

Placebo oral tablet

Drug

Placebo will be administered daily for 7 days, with a study day on day 7.

Primary outcomes

  1. Dipeptidyl peptidase 4 (DPP4)

    Time frame: during study days 1 and 2

    DPP4 activity and antigen concentration

Secondary outcomes

  1. Glucose Area Under the Curve

    Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    Glucose will be measured before after the mixed meal during sitagliptin and placebo. Area under the curve will be calculated based on at least 10 time points after the meal.

  2. Disposition index

    Time frame: Calculated from samples collected before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    Disposition index will be calculated from insulin sensitivity and insulin secretion. These variables will be computed using mathematical modeling of insulin and c-peptide. We will collect insulin and c-peptide at least 10 time points after the meal.

  3. Mean blood pressure

    Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    Measured via an automated blood pressure cuff approximately every 15 minutes

  4. Glucagon-like peptide-1 (GLP-1)

    Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    This is released in response to a meal and rapidly degraded by DPP4. We will collect samples for at least six time points after the meal.

  5. CD26

    Time frame: Before the meal or at baseline (t=-15 or -1 min) on study days 1 and 2

    CD26 is DPP4 on T cells and monocytes.

  6. Surrogate markers of lipolysis

    Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    Triglycerides, free fatty acids; We will collect samples at least six time points after the meal.

  7. Mean heart rate

    Time frame: Before the meal and for 4 hours after (t=-15 through t=240 min) on study days 1 and 2

    Measured via an automated blood pressure cuff approximately every 15 minutes

Sponsors and collaborators

Lead sponsor

University of Pennsylvania

Other

Registry information

Important dates

Study start
2020
Primary completion
2025
Study completion
2026
First posted
Mar 26, 2020
Registry last updated
Jan 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.